The ‘Forbeck Impact’ on Scientific Progress

Some measures of impact are numerical. For example, since its inception, the Foundation has funded and organized: 

  • 1 Forum in Lake Geneva, WI
  • 32 Annual Forums in Hilton Head, SC
  • 12 Scholar Retreats in Lake Geneva, WI
  • 4 International Neuroblastoma meetings with 6 publications from INSS/INRG
  • Funding for the creation of the Interactive International Research Group database (iINRGdb).
  • 13 Focus Meetings
  • Participation of over 600 scientists and clinicians from 22 countries in these meetings
  • 3 Collaborative Research Projects
  • Founded the Neuroblastoma Consortium
  • Sponsor Advances in Neuroblastoma Research (ANR) seminal bi-annual Neuroblastoma meeting
  • Countless papers and collaborations. See publications for papers and clinical applications resulting from meetings.
  • Formation of the Society for Functional Precision Medicine

Collaborative Papers Resulting from Meetings

Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers

Sandra Misale1,2,, Ivana Bozic3,4,, Jingshan Tong5,6, Ashley Peraza-Penton7, Alice Lallo1,8, Federica Baldi1,8, Kevin H. Lin7, Mauro Truini9, Livio Trusolino1,8, Andrea Bertotti1,8, Federica Di Nicolantonio1,8, Martin A. Nowak3,4,10, Lin Zhang5,6, Kris C. Wood7 & Alberto Bardelli1,8
Link to Document

RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis

Peter S. Winter,1 Kristopher A. Sarosiek,2,3 Kevin H. Lin,1 Manja Meggendorfer,4 Susanne Schnittger,4 Anthony Letai,2,3 Kris C. Wood1*
Link to Document

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

Brodeur GM1, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, et al.
Journal of Clinical Oncology, 1993, Aug 11
Many papers have been published from the INSS/ INRG meetings that were initiated from the first Forbeck meeting in 1985 and follow up meetings. Currently the INRGdb has many papers each year published.

Complex oncogene dependence in miR-125a-induced myeloproliferative neoplasm.

Shangqin Guo, Haitao Bai, Cynthia Megyola, Stephanie Halene, Diane S. Krause, David T. Scadden and Jun Lu. PNAS, 109(41):16636-16641, 2012. PMCID: PMC3478612 Jijun Cheng, Shangqin Guo, Suning Chen, Stephen J. Mastriano, Chaochun Liu, Ana C. D’Alessio, Eriona Hysolli, Yanwen Guo, Hong Yao, Cynthia M. Megyola, Dan Li, Jun Liu, Wen Pan, Christine A. Roden, Xiao-Ling Zhou, Kartoosh Heydari, Jianjun Chen, In-Hyun Park, Ye Ding, Yi Zhang, and Jun Lu. An Extensive Network of TET2-Targeting microRNAs Regulates Malignant Hematopoiesis. Cell Reports, 5: 471-481, 2013. PMCID: PMC3834864


Results for Patients

Our work with Kris Sariosek and his mentor, Anthony Letai, has led to current efforts to initiate a clinical trial involving combined JAK and BCL-XL inhibition for the treatment of JAK2-mutant myelofibrosis (refer to Winter et al, Science Signaling 2014 paper above).
— Kris Cameron Wood, Ph.D., Duke University

The concept of the international staging system for neuroblastoma, and subsequent international standards of risk evaluation really grew out of the very 1st Forbeck Foundation meeting. This was a very good thing. I should note that a highly-successful large clinical trial in neuroblastoma, that impacted standard-of-care therapy would not have occurred without help from Jennifer and George Forbeck. Their invaluable assistance, which was provided outside of the context of the Forbeck Foundation, was key to enabling a study that resulted in a New Eng J of Medicine article that reported data which has impacted many hundreds of children with neuroblastoma and will continue to do so in the future.
— C. Patrick Reynolds, M.D., Ph.D., Texas Tech University Health Science Center

Much of our work is in basic science that paves the way for translation. We are also doing some translational work and will see if they materialize into treatment.
— Jun Lu, Ph.D., Yale University

I was working at the time on brain tumor genetics, and since then have been able to expand this work into clinical trials, though it took a long time to reach that point after the meeting.
— Bruce Korf, M.D., Ph.D., University of Alabama of Birmingham